2nd Gene Therapy for Neurological Disorders Europe

Memo

Returning digitally in 2021, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles! Focusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation, this is not one to miss as you seek to accelerate the development of your neurological gene therapy. Discover the latest neurological targets, familiarise yourself with the European landscape, and debate and discuss with the leading minds of the field from the likes of UCB, Lysogene, UniQure and AskBio, as they seek to harness the opportunity and move from rare to common disorders such as Alzheimer’s, Parkinson’s and epilepsy. Focusing on translation and ‘what’s new’ in the gene therapy for neurological disorders field, this year’s 3-day agenda has been developed alongside neurological experts from AskBio, Handl Therapeutics, Novartis and Spark Therapeutics to capture the most pressing challenges and new opportunities facing the field. Discussing rare to common neurological disorders, attend the digital meeting in July to: Hear the latest clinical updates from the most advanced companies to inform your future strategiesDiscover the novel neurological targets being pursued by gene therapy developers to learn of the latest CNS opportunitiesDiscuss how to optimize the use of preclinical models and biomarkers for improved translation and reduced risk to patientsAsk the European Medicines Agency questions related to the specific regulatory challenges of designing trials for both rare and common disordersWeigh up the advantages and disadvantages of established and novel routes of administration for CNS gene therapy deliveryRaise questions to the neurosurgeons at the forefront of neurosurgical delivery and hear their thoughts on the technical challenges facing different programsBe a part of the debate and discussion related to measuring and overcoming CNS immunogenic responses Don’t miss your opportunity to benchmark against your competitors, hear the state of the art technology advances and research in the field, and make new connections at the last digital European meeting, to revolutionise the development and delivery of your neurological gene therapy. Brochure https://go.evvnt.com/749684-0?pid=5569Tickets https://go.evvnt.com/749684-2?pid=5569 Prices:Industry Pricing - Conference Only (First Release) EUR 1299.00Industry Pricing - Conference Only (Second Release) EUR 1449.00Industry Pricing - Conference Only (Third Release) EUR 1599.00Industry Pricing - Conference Only (Fourth Release) EUR 1749.00Industry Pricing - Conference Only (Standard Price) EUR 1899.00 Speakers: Chris Mason, Founder & Chief Scientific Officer, Avrobio, David Cooper, Vice President, Clinical Development, CNS, uniQure, Elena Hernandez Martinez de Lapiscina, Scientific Officer & Clinical Neurologist, European Medicines Agency, Federico Mingozzi, Chief Scientific Officer, Spark Therapeutics, Gavin Corcoran, Chief R&D Officer, Sio Gene Therapies, Grace Liang, Vice President, Clinical Development, Neurocrine Biosciences, Jan Vesper, Professor of Neurosurgery, Heinrich-Heine- University, Jay Barth, Chief Medical Officer, Lexeo Therapeutics, Krystof Bankiewicz, Professor, Neurosurgery, The Ohio State University, Lucie Bruijn, Senior Director, Translational Medicine, Novartis Gene Therapies, Manuela Corti, Assistant Professor, University of Florida, Maria Lopez-Bresnahan, Senior Vice President & Head of Translational Medicine & Clinical Development, Voyager Therapeutics, Martin Citron, Vice President, Neuroscience, UCB, Michael Linden, Chief Scientific Officer, Handl Therapeutics, Nathalie Cartier, CNS, AskBio, Olga Uspenskaya- Cadoz, Vice President, Clinical Development, Prevail Therapeutics, Olivier Danos, Chief Scientific Officer, REGENXBIO, Patrick Ginty, Head of Gene Therapy Regulatory Affairs, Handl Therapeutics, Ralph Laufer, Chief Scientific Officer, Lysogene, Richard Porter, Chief Executive Officer, Corlieve Therapeutics, Samir Koirala, Director of Research Genetic & Neurodevelopmental Disorders, Biogen, Stephane Palfi, Professor & Head of Neurosurgery, Henri Mondor Medical Center, Paris University (UPEC), Suyash Prasad, Chief Medical Officer & Head of Research & Development, Taysha Gene Therapies, William Gray, Professor of Neurosurgery, Cardiff University Time: On Monday July 19, 2021 at 7:00 am (ends Wednesday July 21, 2021 at 3:00 pm)